Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Breeze away breathlessness: fan therapy tested for heart drug side effect

NCT ID NCT07268859

Symptom relief Sponsor: Acibadem University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using a hand fan can prevent or reduce shortness of breath caused by the heart drug ticagrelor. About 110 adults with acute coronary syndrome who are starting ticagrelor will be enrolled. Researchers will track how many people have breathing trouble within two hours of taking the medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 110 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Jan 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Between the ages of 18 and 65, * No severe hearing and vision problems, * Can speak and understand Turkish, * Easy to communicate with, * First-time sufferer of acute coronary syndrome (ACS) for the first time, * Decided to start ticagrelor therapy, * Able to adapt to treatment, * Individuals who volunteered to participate in the research. Exclusion Criteria: * Having any problem that prevents you from communicating cognitively, emotionally and verbally, * Obstructive sleep abnormalities, * Have a disease that affects respiratory function (stage IV cancer, bronchial asthma, COVID-19, lung cancer, pulmonary edema, chronic obstructive pulmonary disease, pulmonary hypertension, pulmonary embolism, pneumonia or bronchitis, etc.), * With metabolic abnormalities, * Intubated after the procedure, * Previously treated with ticagrelor, * Individuals who did not volunteer to participate in the study. Losses to follow up * Individuals who wish to leave the study voluntarily. * Saturation value below 95%, * The one with the arrest, * Who will not be able to fulfill the requirements of the work, * Individuals with life-threatening conditions

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndromes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome Dyspnea

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute coronary syndromes Dyspnea Ticagrelor

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sağlık Bilimleri Üniversitesi Dr. Siyami Ersek Göğüs Kalp ve Damar Cerrahisi Eğitim Araştırma Hastanesi

    RECRUITING

    Istanbul, Üsküdar, 34668, Turkey (Türkiye)

  • İstanbul Üniversitesi-Cerrahapaşa

    NOT_YET_RECRUITING

    Istanbul, Avcılar, 34320, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.